12:00 AM
 | 
Nov 12, 2012
 |  BC Week In Review  |  Company News  |  Deals

Ziarco, Pfizer deal

Newco Ziarco received exclusive, worldwide rights to develop and commercialize a portfolio of four assets from Pfizer for inflammatory and allergic diseases. Pfizer will receive an undisclosed equity stake in Ziarco and is eligible for undisclosed milestones,...

Read the full 165 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >